Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Public ClinicalTrials.gov record NCT01242488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-blind, Placebo-controlled, Dose Ranging Study With an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects With Rheumatoid Arthritis Having Previously Failed TNF-blocker Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapy.
Study identification
- NCT ID
- NCT01242488
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 221 participants
Conditions and interventions
Conditions
Interventions
- CDP6038 Biological
- Tocilizumab (Actemra or RoActemra) Biological
- Placebo sc Other
- Placebo iv Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2010 (Type not available)
- Primary completion
- Jun 2012 (Actual)
- Completion
- Jun 2012 (Actual)
- Last update posted
- Jul 17, 2024
2010 – 2012
United States locations
- U.S. sites
- 74
- U.S. states
- 26
- U.S. cities
- 69
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 166 | Mesa | Arizona | — | — |
| 154 | Paradise Valley | Arizona | — | — |
| 118 | Scottsdale | Arizona | — | — |
| 103 | Hot Springs | Arkansas | — | — |
| 125 | Jonesboro | Arkansas | — | — |
| 127 | Covina | California | — | — |
| 148 | La Jolla | California | — | — |
| 184 | Long Beach | California | — | — |
| 177 | Los Angeles | California | — | — |
| 104 | Palo Alto | California | — | — |
| 149 | Sacramento | California | — | — |
| 158 | San Diego | California | — | — |
| 129 | Santa Maria | California | — | — |
| 164 | Upland | California | — | — |
| 107 | Wildomar | California | — | — |
| 141 | Hamden | Connecticut | — | — |
| 137 | Norwalk | Connecticut | — | — |
| 101 | Trumbull | Connecticut | — | — |
| 111 | Lewes | Delaware | — | — |
| 176 | Aventura | Florida | — | — |
| 186 | Daytona Beach | Florida | — | — |
| 151 | DeBary | Florida | — | — |
| 114 | Jupiter | Florida | — | — |
| 183 | Pinellas Park | Florida | — | — |
| 178 | Sarasota | Florida | — | — |
| 140 | South Miami | Florida | — | — |
| 157 | Tampa | Florida | — | — |
| 130 | Gainesville | Georgia | — | — |
| 162 | Newnan | Georgia | — | — |
| 153 | Savannah | Georgia | — | — |
| 113 | Stockbridge | Georgia | — | — |
| 116 | Idaho Falls | Idaho | — | — |
| 160 | Moline | Illinois | — | — |
| 156 | Rock Island | Illinois | — | — |
| 168 | Springfield | Illinois | — | — |
| 133 | Cedar Rapids | Iowa | — | — |
| 172 | Kansas City | Kansas | — | — |
| 185 | Saint Clair Shores | Michigan | — | — |
| 112 | St Louis | Missouri | — | — |
| 134 | St Louis | Missouri | — | — |
| 102 | Lincoln | Nebraska | — | — |
| 171 | Freehold | New Jersey | — | — |
| 163 | New Brunswick | New Jersey | — | — |
| 152 | Toms River | New Jersey | — | — |
| 174 | Brooklyn | New York | — | — |
| 115 | Rochester | New York | — | — |
| 109 | Belmont | North Carolina | — | — |
| 170 | Charlotte | North Carolina | — | — |
| 150 | Cincinnati | Ohio | — | — |
| 108 | Columbus | Ohio | — | — |
| 100 | Dayton | Ohio | — | — |
| 110 | Oklahoma City | Oklahoma | — | — |
| 165 | Duncansville | Pennsylvania | — | — |
| 117 | Wexford | Pennsylvania | — | — |
| 105 | Nashville | Tennessee | — | — |
| 106 | Nashville | Tennessee | — | — |
| 120 | Amarillo | Texas | — | — |
| 135 | Austin | Texas | — | — |
| 128 | Dallas | Texas | — | — |
| 126 | Houston | Texas | — | — |
| 132 | Houston | Texas | — | — |
| 138 | Houston | Texas | — | — |
| 181 | Houston | Texas | — | — |
| 145 | Mesquite | Texas | — | — |
| 143 | Nassau Bay | Texas | — | — |
| 122 | San Antonio | Texas | — | — |
| 144 | Tomball | Texas | — | — |
| 142 | Victoria | Texas | — | — |
| 121 | Salt Lake City | Utah | — | — |
| 139 | Chesapeake | Virginia | — | — |
| 119 | Seattle | Washington | — | — |
| 175 | Tacoma | Washington | — | — |
| 136 | Beckley | West Virginia | — | — |
| 167 | Clarksburg | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01242488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01242488 live on ClinicalTrials.gov.